Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | Director | May 29, 2026 | June 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kiniksa Pharmaceuticals International, plc
Report date May 29, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary ShareSEC Table I · non-derivative | Direct | 15,345 |
Reported balance
After 2026-05-29 transaction · row 1
1 source rowRow 1 · 2026-05-29 · Exercise / conversion · Acquired 2,799 · Balance 15,345 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. |
| Share OptionSEC Table II · derivative / convertible security · Conversion / exercise price $48.38 · Expires 2036-05-28 | Direct | 12,158 |
Reported balance
After 2026-05-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-29 · Grant · Acquired 12,158 · Balance 12,158 F2: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 2,026 |
Reported balance
After 2026-05-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-29 · Grant · Acquired 2,026 · Balance 2,026 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F3: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-29 · Exercise / conversion · Disposed 2,799 · Balance 0 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4: The RSUs vested in a single installment on May 29, 2026; there was no expiration date for the RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.
F3: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.
F4: The RSUs vested in a single installment on May 29, 2026; there was no expiration date for the RSUs.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Blueprint Medicines Corp
Report date July 17, 2025 · Filed July 21, 2025
Section 16 reporting ended · disclosed 2025-07-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 88,195 |
Reported balance
After 2025-07-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-07-17 · Grant · Acquired 21,353 · Balance 88,195 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F3: Represents shares previously granted to the Reporting Person subject to performance-based vesting conditions ("PSUs"), for which the performance conditions associated with such PSUs had not yet occurred. As of the Effective Time, each PSU was deemed earned based on the greater of target and actual performance as of the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, each PSU was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such PSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award. F4: Includes 259 shares that were previously acquired under the Issuer's employee stock purchase plan. |
| Common StockSEC Table I · non-derivative | Direct | 37,092 |
Reported balance
After 2025-07-17 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2025-07-17 · Disposition to issuer · Disposed 51,103 · Balance 37,092 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F3: Represents shares previously granted to the Reporting Person subject to performance-based vesting conditions ("PSUs"), for which the performance conditions associated with such PSUs had not yet occurred. As of the Effective Time, each PSU was deemed earned based on the greater of target and actual performance as of the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, each PSU was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such PSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit ("RSU"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such RSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-07-17 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2025-07-17 · Other · Disposed 37,092 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.36 | Direct | 0 |
Reported balance
After 2025-07-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-07-17 · Disposition to issuer · Disposed 55,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.05 | Direct | 0 |
Reported balance
After 2025-07-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-07-17 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $81.44 | Direct | 0 |
Reported balance
After 2025-07-17 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-07-17 · Disposition to issuer · Disposed 39,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $86.60 | Direct | 0 |
Reported balance
After 2025-07-17 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-07-17 · Disposition to issuer · Disposed 29,900 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $54.13 | Direct | 0 |
Reported balance
After 2025-07-17 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-07-17 · Disposition to issuer · Disposed 28,500 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.13 | Direct | 0 |
Reported balance
After 2025-07-17 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-07-17 · Disposition to issuer · Disposed 26,125 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.31 | Direct | 0 |
Reported balance
After 2025-07-17 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-07-17 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.15 | Direct | 0 |
Reported balance
After 2025-07-17 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2025-07-17 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $95.12 | Direct | 0 |
Reported balance
After 2025-07-17 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2025-07-17 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $96.57 | Direct | 0 |
Reported balance
After 2025-07-17 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2025-07-17 · Disposition to issuer · Disposed 22,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").
F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.
F3: Represents shares previously granted to the Reporting Person subject to performance-based vesting conditions ("PSUs"), for which the performance conditions associated with such PSUs had not yet occurred. As of the Effective Time, each PSU was deemed earned based on the greater of target and actual performance as of the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, each PSU was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such PSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award.
F4: Includes 259 shares that were previously acquired under the Issuer's employee stock purchase plan.
F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit ("RSU"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such RSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award.
F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Consideration.
F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
ImmunoGen, Inc.
Report date February 12, 2024 · Filed February 12, 2024
Section 16 reporting ended · disclosed 2024-02-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2024-02-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-12 · Disposition to issuer · Disposed 13,090 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie ("Intermediate Sub"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub ("Purchaser"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the "Merger"). F2: At the effective time of the Merger (the "Effective Time"), each restricted stock unit ("RSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of common stock, par value $.01 per share, of the Issuer ("Common Stock") subject to such RSU immediately prior to the Effective Time, multiplied by (ii) $31.26, without interest (the "Merger Consideration"). |
| Deferred Share UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2024-02-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-02-12 · Disposition to issuer · Disposed 50,303 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit ("DSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.72 · Expires 2033-06-14 | Direct | 0 |
Reported balance
After 2024-02-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-12 · Disposition to issuer · Disposed 19,597 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.37 · Expires 2032-06-15 | Direct | 0 |
Reported balance
After 2024-02-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-12 · Disposition to issuer · Disposed 25,556 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.68 · Expires 2031-11-15 | Direct | 0 |
Reported balance
After 2024-02-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-02-12 · Disposition to issuer · Disposed 44,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie ("Intermediate Sub"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub ("Purchaser"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the "Merger").
F2: At the effective time of the Merger (the "Effective Time"), each restricted stock unit ("RSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of common stock, par value $.01 per share, of the Issuer ("Common Stock") subject to such RSU immediately prior to the Effective Time, multiplied by (ii) $31.26, without interest (the "Merger Consideration").
F3: Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit ("DSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.
F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2022 Filed Jul 5, 2022 16:34 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantDeferred Share Unit · Derivative | 3,055 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-007342 · form4-07052022_010742.xml · derivative · entry 1 McCain Tracey L · CIK 0001683600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,655 Underlying: Common Stock · 3,055 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F3 · derivative.exercise_date: The deferred share units vest upon issuance. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document |
| June 29, 2022 Filed Jun 30, 2022 20:21 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-007107 · form4-06302022_010657.xml · derivative · entry 2 McCain Tracey L · CIK 0001683600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Class A Common Shares · 5,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest in their entirety on the first anniversary of the date of grant, June 29, 2022. F3 · derivative.expiration_date: The RSUs vest in their entirety on the first anniversary of the date of grant, June 29, 2022. Read SEC document |
| June 29, 2022 Filed Jun 30, 2022 20:21 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 30,000 | $0.00 Strike: $9.88 | $0.00 |
DisclosureSEC source: 0001415889-22-007107 · form4-06302022_010657.xml · derivative · entry 1 McCain Tracey L · CIK 0001683600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Class A Common Shares · 30,000 shares Expires 2032-06-28 F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of grant. The date of grant is June 29, 2022. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 16:07 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantStock Option (right to buy) · Derivative | 25,556 | $3.37 Strike: $3.37 | $86,123.72 |
DisclosureSEC source: 0001415889-22-006699 · form4-06172022_010652.xml · derivative · entry 2 McCain Tracey L · CIK 0001683600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,556 Underlying: Common Stock · 25,556 shares Expires 2032-06-15 F4 · derivative.exercise_date: Exercisable as to 6,389 shares on each of 9/1/22, 12/1/22, 3/1/23, and 6/1/23, contingent upon the individual remaining a director as of each vesting date. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 16:07 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantDeferred Share Unit · Derivative | 8,712 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-006699 · form4-06172022_010652.xml · derivative · entry 1 McCain Tracey L · CIK 0001683600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,600 Underlying: Common Stock · 8,712 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F2 · derivative.exercise_date: The deferred share units vest ratably over a one-year period in quarterly increments beginning on 9/1/2022, contingent upon the individual remaining a director as of each vesting date. F3 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F3 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 16:13 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantDeferred Share Unit · Derivative | 2,888 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-002537 · edgar.xml · derivative · entry 1 McCain Tracey L · CIK 0001683600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,888 Underlying: Common Stock · 2,888 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest upon issuance. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 21:05 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 1,047 | $56.19 | $58,830.93 |
DisclosureSEC source: 0001415889-22-002736 · form4-03082022_040325.xml · nonDerivative · entry 2 McCain Tracey L · CIK 0001683600 · EVP AND CHIEF LEGAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,227 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $56.18 to $57.07 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 03, 2022 Filed Mar 8, 2022 21:05 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 1,667 | $60.28 | $100,486.76 |
DisclosureSEC source: 0001415889-22-002736 · form4-03082022_040325.xml · nonDerivative · entry 1 McCain Tracey L · CIK 0001683600 · EVP AND CHIEF LEGAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,274 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 01:02 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $61.31 | $0.00 |
DisclosureSEC source: 0001415889-22-002437 · form4-03032022_050323.xml · derivative · entry 2 McCain Tracey L · CIK 0001683600 · EVP AND CHIEF LEGAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-03-01 F2 · derivative.exercise_date: This option vests with respect to 1/48th of the shares underlying the option on April 1, 2022 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 01:02 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-002437 · form4-03032022_050323.xml · nonDerivative · entry 1 McCain Tracey L · CIK 0001683600 · EVP AND CHIEF LEGAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,941 F1 · balance_after: The reported transaction involved the Reporting Person's receipt of grant of 12,500 restricted stock units under Issuer's 2015 Stock Option and Incentive Plan. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 21:01 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $28.36 | $0.00 |
DisclosureSEC source: 0001179110-21-010721 · edgar.xml · derivative · entry 5 McCain Tracey L · CIK 0001683600 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 5,000 shares Expires 2026-10-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on February 22, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · derivative.exercise_date: This option was granted on October 3, 2016 and fully vested as of the date hereof. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 21:01 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 100 | $95.54 | $9,554.00 |
DisclosureSEC source: 0001179110-21-010721 · edgar.xml · nonDerivative · entry 4 McCain Tracey L · CIK 0001683600 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,441 F1 · kind: Effected pursuant to a trading plan adopted on February 22, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 21:01 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 572 | $96.38 | $55,129.36 |
DisclosureSEC source: 0001179110-21-010721 · edgar.xml · nonDerivative · entry 3 McCain Tracey L · CIK 0001683600 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,541 F1 · kind: Effected pursuant to a trading plan adopted on February 22, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.87 to $96.73 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 21:01 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 4,328 | $97.46 | $421,806.88 |
DisclosureSEC source: 0001179110-21-010721 · edgar.xml · nonDerivative · entry 2 McCain Tracey L · CIK 0001683600 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,113 F1 · kind: Effected pursuant to a trading plan adopted on February 22, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.97 to $97.91 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 21:01 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | Exercise / conversionCommon Stock | 5,000 | $28.36 | $141,800.00 |
DisclosureSEC source: 0001179110-21-010721 · edgar.xml · nonDerivative · entry 1 McCain Tracey L · CIK 0001683600 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,441 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on February 22, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes 167 shares that were previously acquired under the Issuer's employee stock purchase plan. Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 20:01 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $28.36 | $0.00 |
DisclosureSEC source: 0001179110-21-009894 · edgar.xml · derivative · entry 4 McCain Tracey L · CIK 0001683600 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 5,000 shares Expires 2026-10-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on February 22, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · derivative.exercise_date: This option was granted on October 3, 2016 and fully vested as of the date hereof. Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 20:01 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 800 | $109.63 | $87,704.00 |
DisclosureSEC source: 0001179110-21-009894 · edgar.xml · nonDerivative · entry 3 McCain Tracey L · CIK 0001683600 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,274 F1 · kind: Effected pursuant to a trading plan adopted on February 22, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.39 to $109.96 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 20:01 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 4,200 | $110.74 | $465,108.00 |
DisclosureSEC source: 0001179110-21-009894 · edgar.xml · nonDerivative · entry 2 McCain Tracey L · CIK 0001683600 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,074 F1 · kind: Effected pursuant to a trading plan adopted on February 22, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.23 to $111.09 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 20:01 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | Exercise / conversionCommon Stock | 5,000 | $28.36 | $141,800.00 |
DisclosureSEC source: 0001179110-21-009894 · edgar.xml · nonDerivative · entry 1 McCain Tracey L · CIK 0001683600 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on February 22, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| September 23, 2021 Filed Sep 27, 2021 20:30 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $28.36 | $0.00 |
DisclosureSEC source: 0001179110-21-008943 · edgar.xml · derivative · entry 5 McCain Tracey L · CIK 0001683600 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 25,000 shares Expires 2026-10-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on February 22, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · derivative.exercise_date: This option was granted on October 3, 2016 and fully vested as of the date hereof. Read SEC document |
| September 23, 2021 Filed Sep 27, 2021 20:30 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 2,921 | $107.75 | $314,737.75 |
DisclosureSEC source: 0001179110-21-008943 · edgar.xml · nonDerivative · entry 4 McCain Tracey L · CIK 0001683600 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,274 F1 · kind: Effected pursuant to a trading plan adopted on February 22, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.74 to $108.08 per share. Read SEC document |
| September 23, 2021 Filed Sep 27, 2021 20:30 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 17,317 | $108.78 | $1,883,743.26 |
DisclosureSEC source: 0001179110-21-008943 · edgar.xml · nonDerivative · entry 3 McCain Tracey L · CIK 0001683600 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,195 F1 · kind: Effected pursuant to a trading plan adopted on February 22, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.18 to $109.08 per share. Read SEC document |
| September 23, 2021 Filed Sep 27, 2021 20:30 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 4,762 | $109.80 | $522,867.60 |
DisclosureSEC source: 0001179110-21-008943 · edgar.xml · nonDerivative · entry 2 McCain Tracey L · CIK 0001683600 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,512 F1 · kind: Effected pursuant to a trading plan adopted on February 22, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.09 to $110.08 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (5) in this form 4. Read SEC document |
| September 23, 2021 Filed Sep 27, 2021 20:30 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | Exercise / conversionCommon Stock | 25,000 | $28.36 | $709,000.00 |
DisclosureSEC source: 0001179110-21-008943 · edgar.xml · nonDerivative · entry 1 McCain Tracey L · CIK 0001683600 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on February 22, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes 422 shares that were previously acquired under the Issuer's employee stock purchase plan. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 20:22 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 33,237 | $0.00 Strike: $14.33 | $0.00 |
DisclosureSEC source: 0001179110-21-007186 · edgar.xml · derivative · entry 1 McCain Tracey L · CIK 0001683600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,237 Underlying: Class A Common Shares · 33,237 shares Expires 2031-06-28 F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of grant. The date of grant is June 29, 2021. Read SEC document |
| March 04, 2021 Filed Mar 5, 2021 22:50 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 1,772 | $86.61 | $153,472.92 |
DisclosureSEC source: 0001179110-21-003009 · edgar.xml · nonDerivative · entry 2 McCain Tracey L · CIK 0001683600 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,852 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 04, 2021 Filed Mar 5, 2021 22:50 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 121 | $89.00 | $10,769.00 |
DisclosureSEC source: 0001179110-21-003009 · edgar.xml · nonDerivative · entry 1 McCain Tracey L · CIK 0001683600 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,624 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.99 to $89.00 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:26 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | GrantStock Option (Right to Buy) · Derivative | 26,125 | $0.00 Strike: $100.13 | $0.00 |
DisclosureSEC source: 0001179110-21-002666 · edgar.xml · derivative · entry 2 McCain Tracey L · CIK 0001683600 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,125 Underlying: Common Stock · 26,125 shares Expires 2031-03-01 F2 · derivative.exercise_date: This option vests with respect to 1/48th of the shares underlying the option on April 1, 2021 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:26 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | GrantCommon Stock | 13,062 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002666 · edgar.xml · nonDerivative · entry 1 McCain Tracey L · CIK 0001683600 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,745 F1 · balance_after: The reported transaction involved the Reporting Person's receipt of a grant of 13,062 restricted stock units under Issuer's 2015 Stock Option and Incentive Plan. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:11 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 18,760 | $0.00 Strike: $25.48 | $0.00 |
DisclosureSEC source: 0001104659-20-080547 · a4.xml · derivative · entry 1 McCain Tracey L · CIK 0001683600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,760 Underlying: Class A Common Shares · 18,760 shares Expires 2030-06-29 F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of grant. The date of grant is June 30, 2020. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 20:28 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 617 | $51.98 | $32,071.66 |
DisclosureSEC source: 0001179110-20-003470 · edgar.xml · nonDerivative · entry 1 McCain Tracey L · CIK 0001683600 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,683 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units.The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 00:10 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | GrantStock Option (Right to Buy) · Derivative | 28,500 | $0.00 Strike: $54.13 | $0.00 |
DisclosureSEC source: 0001179110-20-002961 · edgar.xml · derivative · entry 2 McCain Tracey L · CIK 0001683600 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,500 Underlying: Common Stock · 28,500 shares Expires 2030-03-01 F2 · derivative.exercise_date: This option vests with respect to 1/48th of the shares underlying the option on April 1, 2020 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 00:10 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | GrantCommon Stock | 14,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002961 · edgar.xml · nonDerivative · entry 1 McCain Tracey L · CIK 0001683600 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,300 F1 · balance_after: The reported transaction involved the Reporting Person's receipt of a grant of 14,250 restricted stock units under Issuer's 2015 Stock Option and Incentive Plan. The Reporting Person has reported prior awards of restricted stock units in Table II of Form 4. The total reported in Column 5 includes the 14,250 newly awarded restricted stock units, and 8,050 previously reported restricted stock units, 2,013 of which vested on March 1, 2020. Read SEC document |
| May 29, 2019 Filed May 30, 2019 22:32 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 18,760 | $0.00 Strike: $15.47 | $0.00 |
DisclosureSEC source: 0001179110-19-006867 · edgar.xml · derivative · entry 1 McCain Tracey L · CIK 0001683600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,760 Underlying: Class A Common Shares · 18,760 shares Expires 2029-05-28 F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of grant. The date of grant is May 29, 2019. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:25 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | GrantRestricted Stock Units · Derivative | 8,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-003308 · edgar.xml · derivative · entry 2 McCain Tracey L · CIK 0001683600 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,050 Underlying: Common Stock · 8,050 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments on March 1, 2020, 2021, 2022 and 2023. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments on March 1, 2020, 2021, 2022 and 2023. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:25 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | GrantStock Option (Right to Buy) · Derivative | 29,900 | $0.00 Strike: $86.60 | $0.00 |
DisclosureSEC source: 0001179110-19-003308 · edgar.xml · derivative · entry 1 McCain Tracey L · CIK 0001683600 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,900 Underlying: Common Stock · 29,900 shares Expires 2029-03-01 F1 · derivative.exercise_date: This option vests with respect to 1/48th of the shares underlying the option on April 1, 2019 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 22:08 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $28.36 | $0.00 |
DisclosureSEC source: 0001179110-18-003163 · edgar.xml · derivative · entry 5 McCain Tracey L · CIK 0001683600 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,000 Underlying: Common Stock · 10,000 shares Expires 2026-10-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise reported on this Form 4 was effected pursuant to a trading plan adopted on December 18, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F5 · derivative.exercise_date: This option was granted on October 3, 2016. This option vested with respect to 25% of the shares underlying the option on September 6, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 22:08 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 1,106 | $87.69 | $96,985.14 |
DisclosureSEC source: 0001179110-18-003163 · edgar.xml · nonDerivative · entry 4 McCain Tracey L · CIK 0001683600 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 18, 2017 pursuant to Rule 10b5-1 under the Exchange Act. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.47 to $87.85 per share. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 22:08 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 8,794 | $88.40 | $777,389.60 |
DisclosureSEC source: 0001179110-18-003163 · edgar.xml · nonDerivative · entry 3 McCain Tracey L · CIK 0001683600 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,106 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 18, 2017 pursuant to Rule 10b5-1 under the Exchange Act. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.90 to $88.88 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 22:08 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 100 | $90.75 | $9,075.00 |
DisclosureSEC source: 0001179110-18-003163 · edgar.xml · nonDerivative · entry 2 McCain Tracey L · CIK 0001683600 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,900 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 18, 2017 pursuant to Rule 10b5-1 under the Exchange Act. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 22:08 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | Exercise / conversionCommon Stock | 10,000 | $28.36 | $283,600.00 |
DisclosureSEC source: 0001179110-18-003163 · edgar.xml · nonDerivative · entry 1 McCain Tracey L · CIK 0001683600 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise reported on this Form 4 was effected pursuant to a trading plan adopted on December 18, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 22:33 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | GrantStock Option (Right to Buy) · Derivative | 39,000 | $0.00 Strike: $81.44 | $0.00 |
DisclosureSEC source: 0001179110-18-002415 · edgar.xml · derivative · entry 1 McCain Tracey L · CIK 0001683600 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,000 Underlying: Common Stock · 39,000 shares Expires 2028-02-16 F1 · derivative.exercise_date: This option vests with respect to 1/48th of the shares underlying the option on March 16, 2018 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 21:42 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $36.05 | $0.00 |
DisclosureSEC source: 0001179110-17-002770 · edgar.xml · derivative · entry 1 McCain Tracey L · CIK 0001683600 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 5,000 shares Expires 2027-02-16 F1 · derivative.exercise_date: This option vests with respect to 1/48th of the shares underlying the option on March 16, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document |
| October 03, 2016 Filed Oct 4, 2016 22:22 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $28.36 | $0.00 |
DisclosureSEC source: 0001179110-16-030355 · edgar.xml · derivative · entry 1 McCain Tracey L · CIK 0001683600 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2026-10-03 F1 · date: In accordance with the Issuer's equity award grant policy, this option was granted effective as of the first day of the month following the commencement of the Reporting Person's employment with the Issuer on September 6, 2016. F2 · derivative.exercise_date: This option vests with respect to 25% of the shares underlying the option on September 6, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.